Kestra Medical Technologies, Ltd. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option in Initial Public Offering
Rhea-AI Summary
Kestra Medical Technologies (KMTS), a wearable medical device and digital healthcare company, has announced the full exercise of the underwriters' over-allotment option in its Initial Public Offering (IPO). The underwriters purchased an additional 1,782,352 shares at $17.00 per share.
Following this over-allotment exercise, the total IPO size reached 13,664,704 shares, generating total gross proceeds of approximately $232 million before deducting underwriting discounts, commissions, and other offering expenses.
The offering's lead bookrunners were BofA Securities, Goldman Sachs & Co. , and Piper Sandler, with Wells Fargo Securities and Stifel acting as bookrunners, and Wolfe | Nomura Alliance as co-manager. The registration statement became effective on March 5, 2025.
AI-generated analysis. Not financial advice.
Positive
- Successful completion of IPO with full exercise of over-allotment option
- Substantial capital raise of $232 million in gross proceeds
- Strong underwriter support from major investment banks
Negative
- Potential dilution for existing shareholders due to large share issuance
- Significant offering expenses and underwriting fees will reduce net proceeds
News Market Reaction – KMTS
On the day this news was published, KMTS gained 16.50%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
KIRKLAND, Wash., March 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (“Kestra”), a wearable medical device and digital healthcare company, announced today that the underwriters of Kestra’s initial public offering exercised in full their previously disclosed over-allotment option and have purchased 1,782,352 shares of common stock at a public offering price of
BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners and Wolfe | Nomura Alliance acted as co-manager for the offering.
A registration statement relating to the common shares sold in this offering was filed with the Securities and Exchange Commission and became effective on March 5, 2025. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by facsimile at 212-902-9316, by email at Prospectus-ny@ny.email.gs.com, or by calling 1-866-471-2526; or Piper Sandler, by email at prospectus@psc.com, or by calling (800) 747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
Disclaimer
“Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura and Wolfe Research Securities are serving as underwriters in the offering described herein. In addition, Wolfe Research Securities may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with the offering.
Investor Contact Neil Bhalodkar neil.bhalodkar@kestramedical.com